Form 4: ClearPoint Neuro Officer Jeremy L. Stigall Reports Stock Transactions
SEC Form 4 Filing
ClearPoint Neuro's Chief Business Officer, Jeremy L. Stigall, reports the vesting and sale of shares to cover tax obligations.
Summary
- On March 11, 2025, Jeremy L. Stigall, Chief Business Officer of ClearPoint Neuro, Inc., reported transactions involving ClearPoint Neuro common stock.
- Stigall acquired 8,292 shares of common stock through the vesting of restricted stock units.
- Simultaneously, Stigall disposed of 2,967 shares to satisfy tax withholding obligations at a price of $12.7 per share.
- Following these transactions, Stigall directly owns 64,356 shares of ClearPoint Neuro common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by a company officer. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership by a company officer.
Key Dates
| Date | Description |
|---|---|
| 03/11/2025 | Date of stock transactions: vesting of restricted stock units and sale of shares for tax obligations. |
| 03/13/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.